je.st
news
FDA Decision Signals New Competition For Some Of The Costliest Drugs
2015-03-10 22:49:57| Biotech - Topix.net
McCamish is in charge of biopharmaceutical drug development at the Sandoz division of Switzerland's Novartis. He and his colleagues made the case to a panel of 14 cancer specialists and a group of Food and Drug Administration regulators that a company drug codenamed EP2006 should be approved for sale in the U.S. The drug, brand name Zarxio, is similar to but not quite identical to Amgen's Neupogen, a medicine approved by the FDA back in 1991 to fight infections in cancer patients.
Tags: the
decision
competition
drugs
Category:Biotechnology and Pharmaceuticals